A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

NCT05963997 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer
Locally Advanced Breast Cancer
Breast Cancer

Interventions

DRUG: Samuraciclib
DRUG: Elacestrant Dihydrochloride

Sponsor

Carrick Therapeutics Limited

Collaborators

[object Object]